Merus
Social media
Merus Logo
About Merus
Merus NV is a clinical-stage immuno-oncology company based in the Netherlands, focused on developing bispecific antibody therapeutics for cancer treatment. Its pipeline includes candidates such as Zenocutuzumab (MCLA-128), MCLA-158, MCLA-145, MCLA-129, and ONO-4685, targeting a range of solid tumors and hematological cancers. The company collaborates with partners including Betta Pharmaceuticals, Incyte Corporation, and Gilead Sciences to advance its research and development of innovative antibody-based therapies. Merus was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Address
Uppsalalaan 17, 3rd & 4th floor
Utrecht, 3584 CT
Netherlands
Year founded
2003
Number of employees
200-300
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
